

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **ANNOUNCEMENT**

### **RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023**

On 10 October 2023, Dong-E-E-Jiao released its results estimate for the nine months ended 30 September 2023.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.00% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 22.31% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 10 October 2023, Dong-E-E-Jiao released its results estimate for the nine months ended 30 September 2023, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the nine months ended 30 September 2023 is estimated to range from approximately RMB740.00 million to RMB820.00 million, representing an increase between approximately 44% and 60% as compared to that of approximately RMB512.8984 million for the same period last year, net profit excluding non-recurring gain or loss is estimated to range from approximately RMB660.00 million to RMB740.00 million, representing an increase between approximately 46% and 64% as compared to that of approximately RMB452.2982 million for the same period last year, and basic earnings per share is estimated to range from approximately RMB1.15 per share to approximately RMB1.27 per share (as compared to that of approximately RMB0.80 per share for the same period last year) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

1. Dong-E-E-Jiao continued to promote the implementation of its strategic planning for the “14th Five Year Period” through deeply practising “reshaping values, businesses, organisation and ethos”. It continuously deepens the building “Zi Bu Guo Bao Dong-E-E-Jiao” as a top-tier brand, rejuvenating and renewing the brand comprehensively. It firmly adheres to the dual growth model driven by both pharmaceuticals and health consumer products, systematically develops its research and development planning with “one center” and “three highlands,” promotes product innovation and upgrades, and consolidates core competitiveness. It focuses closely on consumer demands, implements precise marketing for E-Jiao, solidly implements the strategy of the broad category of compound E-Jiao paste products, optimizes and improves the multi-channel construction for “Taohuajie” E-Jiao cake, vigorously promotes convenient forms of E-Jiao products, and achieves stable and positive business growth.
2. As a long-established Chinese brand inheriting the 3,000-year-old E-Jiao culture and with a 71-year history of entrepreneurial development, Dong-E-E-Jiao will seize the opportunities in the Chinese pharmaceutical and health industry, fully integrate into the national healthcare development strategy, and continue to advance the “four reshaping” initiatives. It will continually consolidate the leading position of its “Zi Bu Guo Bao Dong-E-E-Jiao” as a top-tier brand, enrich the development connotation of its dual growth model with diversified and extensive pharmaceuticals and health consumer products, promote the integrated development of the whole industry chain of gelatinous Chinese medicines, and become a promoter, practitioner, and demonstrator of the inheritance and innovation of traditional Chinese medicine culture, and strive to become the “most trusted leader in nourishment and health for the general public.”

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of the financial data, those to be disclosed in the quarterly report for the nine months ended 30 September 2023 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Hong Kong, 11 October 2023

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*